| PH domain-only protein PHLDA3 is a p53-regulated repressor of Akt T Kawase, R Ohki, T Shibata, S Tsutsumi, N Kamimura, J Inazawa, T Ohta, ... Cell 136 (3), 535-550, 2009 | 249 | 2009 |
| Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade S Nakao, Y Arai, M Tasaki, M Yamashita, R Murakami, T Kawase, ... Science translational medicine 12 (526), eaax7992, 2020 | 143 | 2020 |
| PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors R Ohki, K Saito, Y Chen, T Kawase, N Hiraoka, R Saigawa, M Minegishi, ... Proceedings of the National Academy of Sciences 111 (23), E2404-E2413, 2014 | 103 | 2014 |
| p53 target gene AEN is a nuclear exonuclease required for p53-dependent apoptosis T Kawase, H Ichikawa, T Ohta, N Nozaki, F Tashiro, R Ohki, Y Taya Oncogene 27 (27), 3797-3810, 2008 | 89 | 2008 |
| Dissecting functional roles of p53 N‐terminal transactivation domains by microarray expression analysis R Ohki, T Kawase, T Ohta, H Ichikawa, Y Taya Cancer science 98 (2), 189-200, 2007 | 64 | 2007 |
| Novel p53 target gene FUCA1 encodes a fucosidase and regulates growth and survival of cancer cells I Ezawa, Y Sawai, T Kawase, A Okabe, S Tsutsumi, H Ichikawa, ... Cancer science 107 (6), 734-745, 2016 | 61 | 2016 |
| IER5 generates a novel hypo-phosphorylated active form of HSF1 and contributes to tumorigenesis Y Asano, T Kawase, A Okabe, S Tsutsumi, H Ichikawa, S Tatebe, ... Scientific reports 6 (1), 19174, 2016 | 56 | 2016 |
| Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells T Kawase, T Nakazawa, T Eguchi, H Tsuzuki, Y Ueno, Y Amano, T Suzuki, ... Oncotarget 10 (58), 6111, 2019 | 51 | 2019 |
| PHLDA 1, another PHLDA family protein that inhibits Akt Y Chen, M Takikawa, S Tsutsumi, Y Yamaguchi, A Okabe, M Shimada, ... Cancer science 109 (11), 3532-3542, 2018 | 46 | 2018 |
| ASP5878, a novel inhibitor of FGFR1, 2, 3, and 4, inhibits the growth of FGF19-expressing hepatocellular carcinoma T Futami, H Okada, R Kihara, T Kawase, A Nakayama, T Suzuki, ... Molecular Cancer Therapeutics 16 (1), 68-75, 2017 | 44 | 2017 |
| Cancer susceptibility polymorphism of p53 at codon 72 affects phosphorylation and degradation of p53 protein C Ozeki, Y Sawai, T Shibata, T Kohno, K Okamoto, J Yokota, F Tashiro, ... Journal of Biological Chemistry 286 (20), 18251-18260, 2011 | 36 | 2011 |
| Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens Y Kashima, Y Togashi, S Fukuoka, T Kamada, T Irie, A Suzuki, ... Scientific reports 11 (1), 341, 2021 | 24 | 2021 |
| Identification of a novel oncogenic mutation of FGFR4 in gastric cancer T Futami, T Kawase, K Mori, M Asaumi, R Kihara, N Shindoh, S Kuromitsu Scientific Reports 9 (1), 14627, 2019 | 16 | 2019 |
| Genetically engineered vaccinia viruses S Nakao, T Kawase, T Nakamura US Patent 10,888,594, 2021 | 15 | 2021 |
| Identification and characterization of the binding sequences and target genes of p53 lacking the 1st transactivation domain S Suzuki, S Tsutsumi, Y Chen, C Ozeki, A Okabe, T Kawase, H Aburatani, ... Cancer Science 111 (2), 451-466, 2020 | 11 | 2020 |
| Li–Fraumeni syndrome–associated dimer-forming mutant p53 promotes transactivation-independent mitochondrial cell death JH Choe, T Kawase, A Xu, A Guzman, AZ Obradovic, AM Low-Calle, ... Cancer discovery 13 (5), 1250-1273, 2023 | 6 | 2023 |
| Detection method of novel ret fusion N Shindo, K Nishimura, Y Sano, M Asaumi, A Yamanaka, T Futami, ... US Patent App. 13/812,356, 2013 | 5 | 2013 |
| IER5 Is a p53-Regulated Activator of HSF1 That Contributes to Promotion of Cancer T Kawase, Y Chen, R Ohki Heat Shock Proteins in Signaling Pathways, 253-272, 2019 | 3 | 2019 |
| Abstract A172: Preclinical antitumor activity of ASP5878, a novel inhibitor of FGFR1, 2, 3 and 4, in FGF19-expressing hepatocellular carcinoma T Futami, H Okada, R Kihara, T Kawase, A Nakayama, T Suzuki, ... Molecular Cancer Therapeutics 14 (12_Supplement_2), A172-A172, 2015 | 3 | 2015 |
| Novel genetically engineered vaccinia viruses S Nakao, T Kawase, T Nakamura US Patent App. 16/925,039, 2020 | 1 | 2020 |
